FOLH1 and chordoma: While others are currently working on the identification of biomarkers as potential predictive indicators or druggable targets to improve management of GCTB (84), to date, there have been no reports on the expression of PSMA in the vasculature of GCTB or in any other primary bone cancer, such as osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma.